UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy

Leukemia
Johana Díaz-Santaon the behalf of CETLAM Group

Abstract

The treatment of acute myeloid leukemia (AML) is adjusted according to cytogenetic risk factors and molecular markers. Cytarabine remains the main drug to treat AML, and several studies have explored the prognostic relevance of the genotype of cytarabine metabolizing enzymes in AML. Glucuronidation has been identified to be relevant in the cytarabine clearance, but there are still few data concerning the clinical impact of genetic polymorphisms known to condition the activity of UDP-glucuronosyl transferases in AML patients. Here we report the association between the UGT1A1 rs8175347 genotype and the clinical outcome of 455 intermediate-risk cytogenetic AML patients receiving cytarabine-based chemotherapy. Patients with the UGT1A1*28 homozygous variant (associated to a lower UGT1A1 activity) had a lower overall survival (OS) (25.8% vs. 45.5%; p: 0.004). Multivariate analysis confirmed this association (p: 0.008; HR: 1.79; 95% CI: 1.16-2.76). Subgroup analysis showed the negative effect of the UGT1A1*28 homozygous genotype on OS in women (14.8% vs. 52.7%; p: 0.001) but not in men. This lower OS was associated with longer neutropenia after consolidation chemotherapy and with higher mortality without previous relapse, suggesting a...Continue Reading

References

Nov 2, 1995·The New England Journal of Medicine·P J BosmaR P Oude Elferink
Jul 8, 1998·Proceedings of the National Academy of Sciences of the United States of America·E BeutlerA Demina
Jan 23, 2003·Clinical Pharmacokinetics·Janice B Schwartz
Jan 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stefan FröhlingKonstanze Döhner
Mar 10, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Federico InnocentiMark J Ratain
Jan 22, 2005·The New England Journal of Medicine·Brunangelo FaliniUNKNOWN GIMEMA Acute Leukemia Working Party
Dec 22, 2007·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·H JeongJ H Fischer
May 17, 2013·Journal of Human Genetics·Sook Wah YeeCharalambos Andreadis
May 30, 2014·Nature·Hiba Ahmad ZahreddineKatherine L B Borden
Jun 13, 2014·Clinical Pharmacology and Therapeutics·C GuillemetteM Rouleau
Mar 27, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hiba Ahmad Zahreddine, Katherine L B Borden
Sep 12, 2015·Journal of Human Genetics·Lyoung Hyo KimSung-Soo Yoon
Feb 15, 2019·ACS Chemical Biology·Hiba Ahmad ZahreddineKatherine L B Borden

❮ Previous
Next ❯

Citations

Jan 29, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Zhenhui WuYingjian Zeng

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
PCR

Clinical Trials Mentioned

NCT01723657

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.